<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026023</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000074</org_study_id>
    <nct_id>NCT03026023</nct_id>
  </id_info>
  <brief_title>Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant</brief_title>
  <official_title>A Proof of Concept Study for Preemptive Treatment With Grazoprevir and Elbasvir in Donor HCV-positive to Recipient HCV-negative Cardiac Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raymond T. Chung, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept, single center study for the donation of HCV-positive hearts to
      HCV negative recipient patients, with preemptive, interventional treatment with 12-16 weeks
      of grazoprevir and elbasvir (with or without ribavirin) to prevent HCV transmission upon
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 of this study will be a single case study with only one subject enrolled. Once safety
      has been demonstrated and HCV infection transmission shown to be prevented by the protocol,
      the study will expand to 10 additional patients.

      Patients will be selected based on their diminished likelihood of receiving a heart from the
      waitlist within a period during which they would be likely to succumb to severe
      comorbidities. This will be determined in part through use of a patient's listing status (1A,
      1B, 2) and clinical judgment, and the Seattle Heart Failure Model.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV</measure>
    <time_frame>12 Weeks post treatment</time_frame>
    <description>Negative HCV viral RNA at 12 weeks after the last dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (based on number of adverse events and out of range lab values) of grazoprevir and elbasvir (with or without ribavirin) in patients who have undergone cardiac transplantation</measure>
    <time_frame>Upto 16 Weeks</time_frame>
    <description>Safety and tolerability of grazoprevir and elbasvir in the cardiac transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating out of range laboratory results as compared to baseline/pretreatment values per patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Cardiac Transplant Disorder</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment with grazoprevir + elbasvir +/- ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin</intervention_name>
    <description>HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.</description>
    <arm_group_label>Treatment with grazoprevir + elbasvir +/- ribavirin</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient is Age â‰¥ 18 years

          -  Serum ALT within normal limits with no history of liver disease

          -  Lack of sensitization (i.e. PRA &lt; 20%) that would be expected to result in a high
             likelihood of needing aggressive immunosuppression to treat rejection

        Exclusion Criteria:

          -  Sensitization (i.e. PRA &gt;20%)

          -  Any liver disease in recipient

          -  Albumin &lt; 3g/dl or platelet count &lt; 75 x 103/mL

          -  Need for dual organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond T Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond T Chung, MD</last_name>
    <phone>617-724-3836</phone>
    <email>rchung@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna L Gustafson, MS</last_name>
    <phone>617-724-3836</phone>
    <email>jlgustafson@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masschusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenna L Gustafson, MS</last_name>
      <phone>617-724-3836</phone>
      <email>jlgustafson@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Raymond T Chung, MS</last_name>
      <email>rchung@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Emily Bethea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond T. Chung, MD</investigator_full_name>
    <investigator_title>Director of Hepatology</investigator_title>
  </responsible_party>
  <keyword>Heart Transplant</keyword>
  <keyword>Cardiac Transplant</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Zepatier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Elbasvir-grazoprevir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified patient data will be shared with research collaborators for safety and data analysis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

